Evaluating Scholar Rock’s Apitegromab Using the Venture Capital Method
The Venture Capital (VC) method is commonly used to evaluate high-risk, high-reward investments, especially in the biotech sector. In this post, we’ll walk through the VC method step-by-step to estimate the current value of Scholar Rock based on its lead drug candidate, apitegromab, which is currently in Phase 3 trials for treating spinal muscular atrophy (SMA).
1. Calculate Expected Exit Value
We start by estimating the company’s potential worth at the time of exit (e.g., acquisition). Apitegromab is projected to reach peak annual sales of between $1 billion and $1.5 billion. Using a conservative estimate of $1.2 billion in peak sales and a typical exit multiple of 5x sales for the biotech industry, we can calculate the expected exit value as follows:
Expected Exit Value = 1.2 billion USD × 5 = 6 billion USD
2. Adjust for Probability of Success
Given that apitegromab is still in Phase 3, there’s a degree of uncertainty surrounding its approval and successful market entry. Drugs in Phase 3 generally have a 50-60% probability of success. Assuming a 55% chance, we adjust the exit value accordingly:
Risk-Adjusted Exit Value = 6 billion USD × 0.55 = 3.3 billion USD
3. Apply the Discount Rate
Biotech investments are high-risk, so a high discount rate is typically applied to account for this. For our evaluation, we’ll use a 35% discount rate over a 5-year time horizon to bring the risk-adjusted exit value to present value:
Present Value = 3.3 billion USD / (1 + 0.35)^5 ≈ 0.92 billion USD
This present value represents our estimated post-money valuation, adjusted for the risks and time associated with this investment.
4. Calculate Pre-Money Valuation
Now that we have the post-money valuation, we can calculate the pre-money valuation by subtracting the expected funding amount. Assuming Scholar Rock seeks an additional $100 million in funding for further development:
Pre-Money Valuation = 0.92 billion USD – 0.1 billion USD = 0.82 billion USD
Summary
Based on the Venture Capital method, here’s a summary of our valuation:
- Expected Exit Value: $6 billion
- Risk-Adjusted Exit Value: $3.3 billion
- Present Value (Discounted): $920 million
- Pre-Money Valuation: $820 million (assuming a $100 million funding round)
This valuation approach provides a structured estimate of Scholar Rock’s current value, contingent upon apitegromab’s successful commercialization. The final outcome will depend heavily on ongoing trial results and regulatory approvals, making this a high-potential, high-risk investment in the biotech space.